Polycystic Kidney Disease – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Polycystic Kidney Disease – Drugs In Development, 2024 report and make more profitable business decisions.
Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. PKD symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination, and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics.
The Polycystic Kidney Disease drugs in development market research report provide comprehensive information on the therapeutics under development for Polycystic Kidney Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Polycystic Kidney Disease | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 56 molecules, with 51 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Polycystic Kidney Disease therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Polycystic Kidney Disease pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Polycystic Kidney Disease treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Abalone Bio IncAceLink Therapeutics Inc
AeroNeph Therapeutics Inc
Amathus Therapeutics Inc
AmMax Bio Inc
ATLAS Molecular Pharma SL
Camurus AB
Centessa Pharmaceuticals Plc
Chimerna Therapeutics Inc
Chinook Therapeutics Inc
Crinetics Pharmaceuticals Inc
Delta 4 GmbH
Eikonizo Therapeutics Inc
Elicio Therapeutics Inc
Eloxx Pharmaceuticals Inc
exRNA Therapeutics Ltd
Generian Pharmaceuticals Inc
GLG Pharma SA
Goldfinch Bio Inc
Healx Ltd
IC-MedTech Inc
Indiana University
Ipsen SA
Jiangsu Hengrui Medicine Co Ltd
Jiangxi Jemincare Group Co Ltd
Johnson & Johnson
Kadmon Holdings Inc
ManRos Therapeutics
Maze Therapeutics Inc
Mironid Ltd
Mitotherapeutix LLC
Monash University
Nephrogen LLC
Otsuka Pharmaceutical Co Ltd
Pano Therapeutics Inc
Poxel SA
PYC Therapeutics Ltd
Regenacy Pharmaceuticals LLC
Regulus Therapeutics Inc
RHEACELL GmbH & Co KG
Shanghai Alebund Pharmaceuticals Ltd
Surrozen Inc
U.S. Department of Veterans Affairs
University of Kansas
University of Tennessee
Vanda Pharmaceuticals Inc
XORTX Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Polycystic Kidney Disease reports